Office-based therapies for benign prostatic hyperplasia: a review and update

Akhil K. Das, Joon Yau Leong, Claus G. Roehrborn

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) is one of the most common conditions affecting the aging man. Over the years, various treatment modalities with distinct efficacy and safety profiles have emerged in experimental and clinical use. However, only a handful have gained in popularity and stood the test of time. MATERIALS AND METHODS: We provide an update on minimally invasive treatment modalities for BPH, specifically focused on office-based procedures namely the prostatic urethral lift (UroLift) and the convective water vapor ablation therapy (Rezum). RESULTS: Both the UroLift and Rezum have demonstrated excellent efficacy and durability in relieving LUTS in the BPH patient. When compared to the gold standard TURP, these novel therapies can also be performed as an outpatient procedure under local anesthesia, which allows for decreased hospitalization, operative and catheterization times, subsequently allowing for increased cost savings. Moreover, these procedures have no discernable adverse effects on postoperative sexual function, making it a desirable treatment option for many patients. CONCLUSIONS: Both the UroLift and Rezum are minimally invasive treatment options capable of providing rapid, significant and durable relief of LUTS secondary to BPH. They demonstrate comparable efficacy to TURP with the added advantage of preserving sexual function and decreasing patient morbidity and healthcare costs.

Original languageEnglish (US)
Pages (from-to)2-7
Number of pages6
JournalThe Canadian journal of urology
Volume26
Issue number4S1
StatePublished - Aug 1 2019

Fingerprint

Prostatic Hyperplasia
Lower Urinary Tract Symptoms
Transurethral Resection of Prostate
Therapeutics
Cost Savings
Steam
Local Anesthesia
Operative Time
Catheterization
Health Care Costs
Hospitalization
Outpatients
Morbidity
Safety

ASJC Scopus subject areas

  • Urology

Cite this

Office-based therapies for benign prostatic hyperplasia : a review and update. / Das, Akhil K.; Leong, Joon Yau; Roehrborn, Claus G.

In: The Canadian journal of urology, Vol. 26, No. 4S1, 01.08.2019, p. 2-7.

Research output: Contribution to journalArticle

@article{6d2e1578a06e4b948187fc3f3bda1010,
title = "Office-based therapies for benign prostatic hyperplasia: a review and update",
abstract = "INTRODUCTION: Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) is one of the most common conditions affecting the aging man. Over the years, various treatment modalities with distinct efficacy and safety profiles have emerged in experimental and clinical use. However, only a handful have gained in popularity and stood the test of time. MATERIALS AND METHODS: We provide an update on minimally invasive treatment modalities for BPH, specifically focused on office-based procedures namely the prostatic urethral lift (UroLift) and the convective water vapor ablation therapy (Rezum). RESULTS: Both the UroLift and Rezum have demonstrated excellent efficacy and durability in relieving LUTS in the BPH patient. When compared to the gold standard TURP, these novel therapies can also be performed as an outpatient procedure under local anesthesia, which allows for decreased hospitalization, operative and catheterization times, subsequently allowing for increased cost savings. Moreover, these procedures have no discernable adverse effects on postoperative sexual function, making it a desirable treatment option for many patients. CONCLUSIONS: Both the UroLift and Rezum are minimally invasive treatment options capable of providing rapid, significant and durable relief of LUTS secondary to BPH. They demonstrate comparable efficacy to TURP with the added advantage of preserving sexual function and decreasing patient morbidity and healthcare costs.",
author = "Das, {Akhil K.} and Leong, {Joon Yau} and Roehrborn, {Claus G.}",
year = "2019",
month = "8",
day = "1",
language = "English (US)",
volume = "26",
pages = "2--7",
journal = "The Canadian journal of urology",
issn = "1195-9479",
publisher = "Canadian Journal of Urology",
number = "4S1",

}

TY - JOUR

T1 - Office-based therapies for benign prostatic hyperplasia

T2 - a review and update

AU - Das, Akhil K.

AU - Leong, Joon Yau

AU - Roehrborn, Claus G.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - INTRODUCTION: Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) is one of the most common conditions affecting the aging man. Over the years, various treatment modalities with distinct efficacy and safety profiles have emerged in experimental and clinical use. However, only a handful have gained in popularity and stood the test of time. MATERIALS AND METHODS: We provide an update on minimally invasive treatment modalities for BPH, specifically focused on office-based procedures namely the prostatic urethral lift (UroLift) and the convective water vapor ablation therapy (Rezum). RESULTS: Both the UroLift and Rezum have demonstrated excellent efficacy and durability in relieving LUTS in the BPH patient. When compared to the gold standard TURP, these novel therapies can also be performed as an outpatient procedure under local anesthesia, which allows for decreased hospitalization, operative and catheterization times, subsequently allowing for increased cost savings. Moreover, these procedures have no discernable adverse effects on postoperative sexual function, making it a desirable treatment option for many patients. CONCLUSIONS: Both the UroLift and Rezum are minimally invasive treatment options capable of providing rapid, significant and durable relief of LUTS secondary to BPH. They demonstrate comparable efficacy to TURP with the added advantage of preserving sexual function and decreasing patient morbidity and healthcare costs.

AB - INTRODUCTION: Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) is one of the most common conditions affecting the aging man. Over the years, various treatment modalities with distinct efficacy and safety profiles have emerged in experimental and clinical use. However, only a handful have gained in popularity and stood the test of time. MATERIALS AND METHODS: We provide an update on minimally invasive treatment modalities for BPH, specifically focused on office-based procedures namely the prostatic urethral lift (UroLift) and the convective water vapor ablation therapy (Rezum). RESULTS: Both the UroLift and Rezum have demonstrated excellent efficacy and durability in relieving LUTS in the BPH patient. When compared to the gold standard TURP, these novel therapies can also be performed as an outpatient procedure under local anesthesia, which allows for decreased hospitalization, operative and catheterization times, subsequently allowing for increased cost savings. Moreover, these procedures have no discernable adverse effects on postoperative sexual function, making it a desirable treatment option for many patients. CONCLUSIONS: Both the UroLift and Rezum are minimally invasive treatment options capable of providing rapid, significant and durable relief of LUTS secondary to BPH. They demonstrate comparable efficacy to TURP with the added advantage of preserving sexual function and decreasing patient morbidity and healthcare costs.

UR - http://www.scopus.com/inward/record.url?scp=85071754847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071754847&partnerID=8YFLogxK

M3 - Article

C2 - 31481142

AN - SCOPUS:85071754847

VL - 26

SP - 2

EP - 7

JO - The Canadian journal of urology

JF - The Canadian journal of urology

SN - 1195-9479

IS - 4S1

ER -